BioClock: Bright Light Therapy for Depressive Disorders

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

231 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-02-08

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Bright Light Therapy (BLT) is a proven treatment for depression in seasonal and non-seasonal depressive disorders, as well as bipolar disorder. To make BLT more effective and practical in clinical settings and tailor it to individual needs, it is necessary to optimize the treatment approach, understand how the treatment works, and identify patient characteristics that predict response.

This clinical trial has three main goals:

* Optimize the administration of BLT for patients with depressive episodes.
* Gain a deeper understanding of the treatment mechanisms.
* Determine which patients benefit the most from the treatment.

The specific objectives are as follows:

* Investigate whether additional treatments and interventions related to lifestyle and the biological clock can enhance the effects of BLT.
* Examine how BLT influences the body's internal clock and sleep quality, and how these factors contribute to the outcomes.
* Identify patient characteristics and behaviours that can predict treatment outcomes.
* Develop a brain model to better understand the impact of BLT on the brain.

In this study, patients will receive BLT with a light intensity of 10,000 lux for 30 minutes each morning over 5 consecutive days. The treatment duration will range from one to three weeks, depending on the improvement of depressive symptoms. Participants will be randomly assigned to one of three groups:

* Home - Patients will receive BLT at home, following the standard guidelines for light therapy in the Netherlands.
* LightCafé, fixed time: Patients will receive BLT in a café-like setting called the LightCafé, where the focus is not only on symptom improvement but also lifestyle enhancements and fostering social connections. The treatment time will be the same every day.
* LightCafé, varying time: Patients will also receive BLT at the LightCafé, with treatment timing varying each day. Additionally, this group will wear glasses in the evening that filter blue light.

The study includes a baseline phase of up to two weeks, a treatment phase of up to three weeks, and a three-month follow-up phase. Patients will wear a motion watch to assess sleep-wake behaviour and physical activity during the day. Additionally, they will wear a broach that measures their personal light exposure throughout the day. Eight one-minute questionnaires per day will be sent to the participants' smartphones to assess vitality, sleep, and mood during the treatment. Predictors of treatment response, such as clinical characteristics, sleep measures, circadian parameters, and light-related behaviours, will be evaluated at baseline. In a small group of patients, salivary melatonin curves will be assessed before and after treatment. MRI scans will provide insights into functional and structural brain changes following light therapy treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Light Therapy for Depression in Adolescent Outpatients

NCT05823090

Depression Adolescent - Emotional Problem

COMPLETED PHASE4

Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

NCT05850689

Major Depressive Disorder

RECRUITING PHASE3

Clinical Trial of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

NCT04985942

Major Depressive Disorder

COMPLETED PHASE3

EEG Biomarkers for Predicting Response to Antidepressant Therapy

NCT00289523

Major Depressive Disorder

COMPLETED

Study to Assess the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder

NCT06058013

Major Depressive Disorder

RECRUITING PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Depression, Unipolar Depression, Bipolar

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Light@Home

Standard Care - BLT in the home environment

Group Type ACTIVE_COMPARATOR

Bright Light Therapy

Intervention Type PROCEDURE

In this study, Bright Light Therapy (BLT) will be administered according to Dutch depression guidelines, using Innolux LED light lamp (3800K, 10,000 lux). BLT will be given for one work week (Mon-Fri), 7:30-10:30 AM, 30 mins/session. Patients can have breakfast, read, or use devices. Treatment effectiveness will be evaluated using Self-Rated Quick Inventory of Depressive Symptoms (QIDS-SR). If remission is achieved (QIDS-SR \< 6), no additional treatment is given. If response is insufficient (QIDS-SR ≥ 6), 5 more sessions will be added in the following week, with maximum two extensions (1-3 weeks total).

LightCafé

BLT will be administered in a specialized cafe, under the supervision of clinical staff, promoting lifestyle changes and social interaction.

Group Type EXPERIMENTAL

Bright Light Therapy

Intervention Type PROCEDURE

In this study, Bright Light Therapy (BLT) will be administered according to Dutch depression guidelines, using Innolux LED light lamp (3800K, 10,000 lux). BLT will be given for one work week (Mon-Fri), 7:30-10:30 AM, 30 mins/session. Patients can have breakfast, read, or use devices. Treatment effectiveness will be evaluated using Self-Rated Quick Inventory of Depressive Symptoms (QIDS-SR). If remission is achieved (QIDS-SR \< 6), no additional treatment is given. If response is insufficient (QIDS-SR ≥ 6), 5 more sessions will be added in the following week, with maximum two extensions (1-3 weeks total).

LightCafé+

Treatment will be identical to the second arm but now complemented with the use of blue-light blocking glasses in the evening and the adoption of personalized BLT timing based on sleep-wake patterns

Group Type EXPERIMENTAL

Bright Light Therapy

Intervention Type PROCEDURE

In this study, Bright Light Therapy (BLT) will be administered according to Dutch depression guidelines, using Innolux LED light lamp (3800K, 10,000 lux). BLT will be given for one work week (Mon-Fri), 7:30-10:30 AM, 30 mins/session. Patients can have breakfast, read, or use devices. Treatment effectiveness will be evaluated using Self-Rated Quick Inventory of Depressive Symptoms (QIDS-SR). If remission is achieved (QIDS-SR \< 6), no additional treatment is given. If response is insufficient (QIDS-SR ≥ 6), 5 more sessions will be added in the following week, with maximum two extensions (1-3 weeks total).

Blue Light Blocking Glasses

Intervention Type DEVICE

Plastic, orange-coloured glasses that primarily block blue light. To be worn in the evening.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Bright Light Therapy

In this study, Bright Light Therapy (BLT) will be administered according to Dutch depression guidelines, using Innolux LED light lamp (3800K, 10,000 lux). BLT will be given for one work week (Mon-Fri), 7:30-10:30 AM, 30 mins/session. Patients can have breakfast, read, or use devices. Treatment effectiveness will be evaluated using Self-Rated Quick Inventory of Depressive Symptoms (QIDS-SR). If remission is achieved (QIDS-SR \< 6), no additional treatment is given. If response is insufficient (QIDS-SR ≥ 6), 5 more sessions will be added in the following week, with maximum two extensions (1-3 weeks total).

Intervention Type PROCEDURE

Blue Light Blocking Glasses

Plastic, orange-coloured glasses that primarily block blue light. To be worn in the evening.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age between 18 and 65.
* Diagnosis of unipolar or bipolar depression (seasonal or non-seasonal) as assessed with the Mini-International Neuropsychiatric Interview (M.I.N.I.)
* A current depressive episode (a score of 6 or higher on the Quick Inventory of depressive symptomatology Self Report (QIDS-SR)
* Sufficient knowledge of Dutch or English language to fill in questionnaires
* Provided Informed consent

Exclusion Criteria

* A current (hypo)manic or mixed episode (as assessed with the M.I.N.I.)
* Current psychotic episode (as assessed with the M.I.N.I.)
* Prominent active suicidality (score 10 or higher on the M.I.N.I. module)
* Antidepressant therapy (medication, psychotherapy or BLT, or other forms of specific treatments for depression) that started less than 2 months prior to study entry
* participants with bipolar disorder should be in mood-stabilizing treatment for at least 1 month in a recommended dosage,
* Use of melatonin or agomelatine in the last month
* Current use of antibiotics
* Current use of light sensitivity increasing medication
* Travelled across more than 1 time zone during past month or during the treatment
* Travelled to sunny holiday locations/winter sports during past month
* pre-existing eye and skin disorders (retinitis pigmentosa, porphyria, chronic actinic dermatitis and sun-induced urticaria)
* Systemic disorders with potential retinal involvement (rheumatoid arthritis and systemic lupus erythematosus)
* Suffering from colour blindness (assessed by Ishihara colour plates)
* Participated in night shift work in the last three months
* (Retinal) blindness, severe cataract and glaucoma
* Light-induced migraine or epilepsy
* Pregnancy, or parents with a child younger than 18 months old

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No